Researchers based at the City University of New York (CUNY) have designed a deep learning artificial intelligence (AI) model that can improve preclinical predictions of drug responses in humans. As outlined in the Oct. 17, 2022, online issue of Nature Machine Intelligence, the researchers believe their model – a context-aware deconfounding autoencoder (CODE-AE) – can help improve the quality of early drug response prediction and help reduce subsequent clinical trial failures. Read More
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway. Read More
Guangzhou Zhiyi Biotechnology Co. Ltd. has received IND approval from the FDA to conduct a phase I study in the U.S. with SK-10 for the treatment of chemotherapy-induced diarrhea. Read More
At the recent European Association of Nuclear Medicine meeting in Barcelona, researchers from the British Columbia Cancer Research Institute and the University of British Columbia reported the development and preclinical evaluation of bispecific radiotracers designed to target prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP). Read More
Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders. Read More
Chiesi Farmaceutici SpA has described new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Read More
The use of cannabis and childhood trauma have been proposed as environmental factors impacting the risk of psychosis. Recent findings have suggested a link between genetic variants in the cannabinoid receptor 1 gene (CNR1) and cannabis use with the risk of psychosis development. Read More
The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has presented new imidazo[1,2-b]pyridazine-based tricyclic compounds acting as serine/threonine-protein kinase haspin (GSG2) inhibitors and reported to be useful for the treatment of cancer. Read More
Jacobio Pharmaceuticals Co. Ltd. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer. Read More
Vitti Labs LLC has received FDA clearance of its IND for EV-Pure, an allogenic exosomal product, for women with primary ovarian insufficiency. Read More
Medshine Discovery Inc. has presented new pyrimidine derivatives acting as leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of neurodegeneration. Read More
